Home Alzheimer’s Disease FDA Accepts sNDA for Zanubrutinib for Treatment of Waldenström Macroglobulinemia

FDA Accepts sNDA for Zanubrutinib for Treatment of Waldenström Macroglobulinemia

The FDA has accepted a supplemental new drug application (sNDA) for the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for the treatment of adult patients with Waldenström macroglobulinemia (WM), according to the drug’s developer, BeiGene.1

A prescription drug user fee act (PDUFA) target action date has been set by the FDA for October 18, 2021.

The sNDA submission was primarily based on safety and efficacy data from the global phase 3 ASPEN trial (NCT03053440) of zanubrutinib compared with ibrutinib (Imbruvica) for the treatment of WM, with supportive data from a pivotal phase 2 trial (NCT03332173) of zanubrutinib in relapsed or refractory WM conducted in China and a global phase 1/2 trial (NCT02343120) in patients with B-cell malignancies. Overall, the culmination of these trials included data from 351 patients with WM.

Additionally, safety data from 779 patients…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments